Volume 25, Number 7—July 2019
Research
Asymptomatic Dengue Virus Infections, Cambodia, 2012–2013
Table 1
Surveillance data from perifocal investigations for asymptomatic dengue virus, Cambodia, 2012–2013*
Surveillance data |
2012 |
2013 |
Total |
No. participants | 2,391 | 5,569 | 7,960 |
No. villages investigated | 35 | 77 | 104 |
No. perifocal investigations conducted | 47 | 102 | 149 |
Mean no. participants per perifocal investigation |
51 |
55 |
53 |
Confirmed infections, no. (%) | 88 | 258 | 346 |
Strictly asymptomatic | 5 (5.7) | 21 (8.1) | 26 (7.5) |
Afebrile | 33 (37.5) | 77 (29.8) | 110 (31.2) |
Symptomatic |
83 (94.3) |
237 (91.9) |
320 (92.5) |
Attack rate/1,000 participants, % | 36.8 | 46.3 | 43.5 |
Asymptomatic infections | 2.1 | 3.8 | 3.3 |
Symptomatic infections | 34.7 | 42.6 | 40.2 |
Afebrile infections |
13.8 |
13.8 |
13.8 |
Symptoms at diagnosis or follow-up, no. (%) | 83 | 237 | 320 |
Fever | 55 (66.2) | 180 (75.9) | 236 (73.8) |
Headache | 52 (62.7) | 169 (71.3) | 221 (69.1) |
Muscle pain | 16 (19.3) | 73 (30.8) | 89 (27.8) |
Retro-orbital pain | 17 (20.5) | 73 (30.8) | 90 (28.1) |
Joint pain | 17 (20.5) | 68 (28.7) | 85 (26.5) |
Rash | 15 (18.1) | 53 (22.4) | 68 (21.3) |
Any bleeding |
13 (15.7) |
50 (21.1) |
63 (19.7) |
Hospitalizations, no. (%) |
3 (3.5) |
8 (3.3) |
11 (3.3) |
DENV infections | 88 | 258 | 346 |
Serotype, no. (%) | |||
DENV-1 | 82 (98.8) | 188 (72.9) | 270 (78.0) |
DENV-2 | 1 (1.2) | 36 (13.9) | 37 (10.7) |
DENV-3 | 0 | 2 (0.8) | 2 (0.6) |
DENV-4 | 0 | 31 (12.0) | 31 (9.0) |
DENV-1 and DENV-2 | 0 | 1 (0.4) | 1 (0.3) |
Missing | 5 | 0 | 5 |
*Participants 0.5–30 years of age in 2012 and 0.5–20 years of age in 2013. DENV, dengue virus.
1These authors contributed equally to this article.
2Current affiliation: GlaxoSmithKline Vaccines Research and Design, Singapore.